Abstracts of the 36th Scandinavian Congress of Rheumatology: Reykjavik, Iceland, September 1st-3rd, 2016
Gespeichert in:
| Körperschaft: | |
|---|---|
| Weitere Verfasser: | |
| Format: | Tagungsbericht Buch |
| Sprache: | English |
| Veröffentlicht: |
Milton Park, Abingdon
Taylor & Francis
2016
|
| Schriftenreihe: | Scandinavian journal of rheumatology
Supplement ; 128 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | 77 Seiten Illustrationen, Diagramme |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV043826319 | ||
| 003 | DE-604 | ||
| 005 | 20190222 | ||
| 007 | t | ||
| 008 | 161014s2016 a||| |||| 10||| eng d | ||
| 035 | |a (OCoLC)968257326 | ||
| 035 | |a (DE-599)BVBBV043826319 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 111 | 2 | |a Scandinavian Congress of Rheumatology |n 36. |d 2016 |c Reykjavik |j Verfasser |0 (DE-588)1114844047 |4 aut | |
| 245 | 1 | 0 | |a Abstracts of the 36th Scandinavian Congress of Rheumatology |b Reykjavik, Iceland, September 1st-3rd, 2016 |c editors: Guðrún Björk Reynisdóttir, Björn Guðbjörnsson |
| 264 | 1 | |a Milton Park, Abingdon |b Taylor & Francis |c 2016 | |
| 300 | |a 77 Seiten |b Illustrationen, Diagramme | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Scandinavian journal of rheumatology : Supplement |v 128 | |
| 650 | 0 | 7 | |a Rheumatismus |0 (DE-588)4049836-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Rheumatologie |0 (DE-588)4128646-7 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 689 | 0 | 0 | |a Rheumatologie |0 (DE-588)4128646-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Rheumatismus |0 (DE-588)4049836-0 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Reynisdóttir, Guðrún Björk |4 edt | |
| 830 | 0 | |a Scandinavian journal of rheumatology |v Supplement ; 128 |w (DE-604)BV000003191 |9 128 | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029237208&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029237208 | ||
Datensatz im Suchindex
| _version_ | 1804176685591953408 |
|---|---|
| adam_text | Titel: Abstracts of the 36th Scandinavian Congress of Rheumatology
Autor: Scandinavian Congress of Rheumatology, 36., 2016, Reykjavik
Jahr: 2016
SCANDINAVIAN JOURNAL OF
RHEUMATOLOGY
CONTENTS VOLUME 45 SUPPLEMENT 128__2016
ORAL PRESENTATIONS
Thursday Symposium
1 OP01
Has the improved management of newly diagnosed rheumatoid
arthritis (RA) lowered the excess risk of acute coronary
syndrome (ACS)?
M Holmqvist, L Ljung, J Askling
Friday Symposium
2 OP02
Toward next-generation rheumatology: from clinical research to
understanding and back
T Huizinga, A van der Helm, U Scherer, L Trouw, R Toes
2 OP03
Metacarpal osteomyelitis is a rare differential diagnosis in common
causes of hand pain: a case report
BA Frederiksen, MJ Velander, IMJ Hansen
3 OP04
HLA-B27 status is associated with TNF-cr inhibitor treatment
outcomes in ankylosing spondylitis and non radiographic
axial spondylarthritis. An observational cohort study
from the nationwide DANBIO registry
B Glintborg, IJ Serensen, M 0stergaard, NS Krogh, AA Mohamoud,
LS Andersen, JL Raun, 0 Hendricks, MR Kowalski, L Danieisen,
SR Christensen, N AI Chaer, R Pelck, H Nordin, JK Pedersen,
DGA Kraus, IMJ Hansen, J Espesen, A Schlemmer, AG Loft,
L Salomonsen, L Dreyer, ML Hetland
3 OP05
Secukinumab provides sustained improvements in the signs and
symptoms of active ankylosing spondylitis: 2-year results from a
phase 3 trial (MEASURE 2)
T Sokka-lsler, H Marzo-Ortega, J Sieper, R Martin, H Richards
4 0P06
Characterization of systemic lupus erythematosus subgroups with
features of antiphospholipid syndrome or Sjogren s syndrome using
affinity proteomics
H Idborg, A Zandian, JT Gustafsson, I Gunnarsson, E Svenungsson,
P Nilsson, P-J Jakobsson
4 OP07
Three months clinical outcomes from a nationwide non-medical
switch from originator to biosimilar infliximab in patients with
inflammatory arthritis. Results from the DANBIO registry
B Glintborg, IJ Sorensen, DV Jensen, NS Krogh, AG Loft, A Colic,
J Espesen, J Olsen, 0 Hendricks, J Grydehej, IMJ Hansen,
MV S0rensen, S Chrysidis, A Linauskas, HM Lindegaard,
BL Andersen, N Manilo, M Klarlund, LS Andersen, H Nordin,
S Kristensen, ML Hetland
5 OP08
The lung microbiome in rheumatoid arthritis and associated
local/systemic autoimmunity
V Joshua, J Scher, CUbeda,AArtacho, L Segal, J Grunewald, A Catrina
6 0P09
Obesity is associated with worse clinical outcomes yet limited
radiographic progression in early rheumatoid arthritis
A Levitsky, S Saevarsdottir, K Brismar, K Hambardzumyan,
C Lourdudoss, R van Vollenhoven
6 OP10
Non-medical switch from originator to biosimilar infliximab in
patients with inflammatory arthritis: impact on s-infliximab and
antidrug antibodies. Results from the Danish Rheumatological
Biobank and the DANBIO registry
B Glintborg, T Kringelbach, E Hegdall, IJ Serensen, DV Jensen,
AG Loft, 0 Hendricks, IMJ Hansen, N Bolstad, DJ Warren, J Gehin,
G Göll, KL Gron, G Eng, C Enevold, CH Nielsen, JS Johansen, ML Hetland
7 OP11
Effect of bariatric surgery on the incidence of hypemricaemia and gout
C Maglio, A Rudin, L Carlsson
Saturday Symposium
8 0P12
Baricitinib vs. placebo or adalimumab in patients with active rheumatoid
arthritis and an inadequate response to background methotrexate
therapy: results of a phase 3 study
P Taylor, EC Keystone, D van der Heijde, Y Tanaka, T Ishii, K Emoto,
L Yang, VArora, C Gaich, T Rooney, D Schlichting, WL Macias,
S De Bono, ME Weinblatt, E Larsson
8 0P13
Characterization of extracellular histidyl-tRNA synthetase in myositis
P-J Jakobsson, C Femandes-Cerqueira, A Sohrabian, I Albrecht,
A Notarnicola, E Ossipova, J Lengqvist, M Fathi, GJ Pruijn,
J Grunewald, J Rönnelid, IE Lundberg
8 0P14
How do women with lupus manage fatigue? A focus group study
A0 Kier, J Midtgaard, A Berggreen, G Bukh, RB Hansen,
KS Hougaard, L Dreyer
9 0P15
Egill Skallagrlmsson: How a Viking s bone disease led to the cure of
osteoporosis
PJO Stride
9 0P16
The rate of nurse consultations is higher with senior physicians than
junior physicians: impact on the economy
MB Hansen, A Emamifar, M Hai van Bui Hansen, S Mousavi,
IMJ Hansen
www.scanrlirheumatol.dk
Contents
9 0P17
Clinical decision support system in osteoporosis in comparison to
NOGG guidelines and an osteology specialist
HT Guömundsson, KE Hansen, BV Halldorsson, BR Ludviksson,
B Gudbjornsson
POSTER PRESENTATIONS
Pathogenesis in rheumatoid arthritis
10 PP01
Association between number and type of different ACPA fine
specificities and parenchymal lung changes in high-resolution
computed tomography in patients with early rheumatoid arthritis
V Joshua, K Chatzidionysiou, G Reynisdottir, AH Hensvold,
M Hansson, G Serre, J Grunewald, A Catrina
10 PP02
Anti-citrullinated protein antibodies promote synovial fibroblast
migration and adhesion through a peptidylarginine deiminase
(PAD)-dependent pathway
M Sun, V Joshua, AH Hensvold, SB Catrina, C Ospelt,
V Malmström, K Amara, M Engström, H Wähämaa,
B Rethi, AI Catrina
11 PP03
Immature dendritic cells are potent osteoclast precursors in RA and
are targeted by autoantibodies against citrullinated proteins
A Krishnamurthy, J Ytterberg, M Sun, V Joshua, H Wähämaa,
N Tarasova, K Amara, V Malmström, B Rethi, AI Catrina
11 PP04
The B-cell compartment in manifest rheumatoid arthritis
I Gjertsson, K Thorarinsdottir, A Camponeschi, M Bergqulst,
L Jacobsson, l-L Märtensson
12 PP05
Utility of survivin measurements for early recognition of rheumatoid
arthritis in patients with clinically suspect arthralgia
M Bokarewa, M Turkkila, M Eriandsson, S Bratt, R Pullerits
12 PP06
Calprotectin levels correlate with inflammation in early RA before and
after 12 months of DMARD treatment
MK Jonsson, HB Hammer, HH Nordal, A-B Aga, IC Olsen, KA Bmkstad,
S Lillegraven, TK Kvien, B-TS Fevang, EA Haavardsholm
13 PP07
Calprotectin (S100A8/A9, MRP8/14) is more strongly associated with
disease activity in rheumatoid arthritis when measured in EDTA
plasma than in serum
HH Nordal, A-K Halse, HB Hammer
14 PP08
PD-1 in RA
H Kristjansdottir, G Gröndal, K Eriendsson, K Steinsson
Clinical aspect of rheumatoid arthritis
14 PP09
Smoking and persistent disease activity are associated with an
increased risk of rapid joint destruction in patients with early
rheumatoid arthritis
E Rydell, C Book, KForslind, J-A Nilsson, L Jacobsson, C Turesson
15 PP10
Smoking and response to rituximab in anti-CCP positive and
negative rheumatoid arthritis: results from an International
European Collaboration
K Chatzidionysiou, E Lie, G Lukina, M Heitand, E Hauge, K Pavelka,
C Gabay, D Nordstrom, H Canhäo, M Tomsic, J Gomez-Reino,
I Ancuta, T Kvien, R van Vollenhoven, S Saevarsdottir
16 PP11
Deficiencies in vitamin D and folic acid in patients with newly
diagnosed rheumatoid arthritis have no influence on
treatment response
A Emamifar, IMJ Hansen
16 PP12
Shift work may be associated with an increased risk of rheumatoid
arthritis in women but not in men
L Arvidsson, U Bergstriom, M Pikwer, J-Ä Nilsson, L Jacobsson,
C Turesson
16 PP13
Work participation after 2 years is excellent in early RA patients
treated according to a treat-to-target strategy
S Lillegraven, MD Mjaavatten, NP Sundlisaeter, A-B Aga, IC Olsen,
T Uhlig, DH Solomon, TK Kvien, EA Haavardsholm
17 PP14
Patient and rheumatology staff evaluation of the Health
Assessment Questionnaire (HAQ) in an outpatient clinic.
Results of a pilot study
P Toftegaard, IMJ Hansen
18 PP15
Rheumatoid arthritis and hearing impairment: a review
A Emamifar, K Bjoemdal, IMJ Hansen
18 PP16
Factors affecting the need for orthopaedic surgery in patients with
rheumatoid arthritis. Results from 1010 patients diagnosed with RA
from 1972 to 2009
TW Nystad, U Havelin, 0 Fumes, BTS Fevang
Treatment in rheumatoid arthritis
19 PP17
Do specific ACPAs or other autoantibodies in a novel assay predict
response to methotrexate monotherapy in patients with early and
DMARD-naive RA?
S Saevarsdottir, L Klareskog, M Hansson, J Eriksson, M Johannesson,
R Holmdahl, K Skriner, G Serre, L Mathsson-Alm, RF van Vollenhoven,
DvanderWoude, RAIIaart, LAIfredsson, IMclnnes, J Rönnelid, JAskling
19 PP18
Lack of early change in DAS28-4(ESR) predicts the likelihood of
achieving LDA at month 6: tofacitinib monotherapy vs. MTX in
MTX-nai ve patients with RA
R DeMasi, E Keystone, R van Vollenhoven, B Wilkinson, L Fallon,
L-J Hwang, D Chapman, EB Lee
20 PP19
Tofacitinib, an oral JAK inhibitor, in the treatment of RA: safety and
clinical and radiographic efficacy in open-label, long-term extension
studies over 7 years
R DeMasi, J Wollenhaupt, J Silverfield, EB Lee, K Kwok, I Lazariciu,
C Nduaka, C Cornell, L Wang
www.scandjrheumatol.dk
Contents
20 PP20
Efficacy and safety of baricitinib in patients with rheumatoid arthritis
and inappropriate response to conventional disease-modifying
anti-rheumatic drugs: 24-week phase 3 RA-BUILD study
summary results
P Emery, M Krogulec, RB Alonso, M Rossini, F Raeman, D Walker,
AP Ghizdavescu, I Irto, ML Rentero, M Casillas, I De la Torre,
M Dougados, E Larsson
21 PP21
Efficacy and safety of baricitinib in patients with active rheumatoid
arthritis and inadequate response to tumour necrosis factor inhibitors:
the 24-week phase 3 RA-BEACON study
0 Zamani, B Combe, H-P Tony, JS Burson, H Tahir, M 0stergaard,
B Augendre-Ferrante, A Beselin, E Larsson, M Casillas, J Smolen
22 PP22
Baricitinib, methotrexate, or baricitinib plus methotrexate in patients
with early rheumatoid arthritis who had received limited/no treatment
with disease-modifying anti-rheumatic drugs: Phase 3 trial results
R Fieischmann, T Takeuchi, DE Schlichting, WL Macias, T Rooney,
S Gurbuz, I Stoykov, SD Beattie, W-L Kuo, M Schiff, E Larsson
22 PP23
Efficacy and safety of sirukumab in patients with active rheumatoid
arthritis despite disease-modifying anti-rheumatic drug treatment:
results of a randomized, double-blind, placebo-controlled study
T Takeuchi, C Timme, G Karpouzas, S Sheng, WXu, R Rao, K Fei, B Hsu
23 PP24
Response and radiographic progression in biologic-naive and biologic-
experienced patients with rheumatoid arthritis treated with sirukumab
C Thome, G Karpouzas, T Takeuchi, S Sheng, WXu, S Xu, R Kurrasch,
KFei, BHsu
24 PP25
Improvement in measures of prevalent depressed mood and anhedonia
(PDMA) and fatigue in a randomized, double-blind, placebo-controlled,
phase 2 study of sirukumab in patients with rheumatoid arthritis
B Hsu, D Wang, Y Sun, G Salvadore, J Singh, M Curran, W Drevets,
G Wittenberg, G Chen
24 PP26
mPGES-1 deletion increases prostacyclin and evades the elevated
systemic ADMA associated with COX-2 inhibitors: relevance to
cardiovascular safety of mPGES-1 inhibitors
J Raouf, N Kirkby, B Ahmetaj-Shala, B Liu, SM MRes, M Korotkova,
D Zeldin, Y Zhou, P-J Jakobsson, J Mitchell
Register in rheumatology
25 PP27
Rheumatoid arthritis (RA) treatment guidelines in Finland
T Sokka, L Pirifä, E Nikiphorou, M Hakala, M Kauppi, K Taimen, K Puoiakka
25 PP28
Screening for tuberculosis before TNF-cr treatment in routine
rheumatic care. Results from the nationwide ICEBIO registry
TM Bjorgutfsson, G Grondai, T Blondal, B Gudbjomsson; on behalf of ICEBIO
26 PP29
There is a risk of overtreatment when the Disease Activity Score in
28 joints is based solely on subjective parameters. A cross-sectional,
exploratory, DANBIO study
A Emamifar, RA Andreasen, MN van Bui Hansen, IM J Hansen
27 PP30
The physician efficiency index (PEI) for specialists in rheumatology
is significantly higher than the PEI for junior physicians in
rheumatology residency training
A Emamifar, MB Hansen, MH van Bui Hansen, S Mousavi, IMJ Hansen
27 PP31
Risk of multiple sclerosis during tumour necrosis factor inhibitor
treatment for arthritis: a population-based study from DANBIO and
the Danish Multiple Sclerosis Registry (DMSR)
L Dreyer, M Magyar! B Laursen, R Cordtz, F Sellebjerg, H Locht
28 PP32
Significance of the lower reporting limit and intraindividual
biological variability for C-reactive protein in calculating
the Disease Activity Score in 28 joints (DAS28):
theoretical considerations
A Emamifar, RA Andreasen, MN van Bui Hansen, S Antonsen,
IMJ Hansen
Spondyloarthritides
29 PP33
Disease activity and increased risk of cardiovascular death among
patients with psoriatic arthritis
KJuneblad, G-MAIenius, S Rantapaä-Dahlqvist
29 PP34
Do male psoriatic arthritis patients get easier access to biological
DMARDs?
B Michelsen, DM Soldal, A Kavanaugh, G Haugeberg
30 PP35
Tumour necrosis factor inhibitor treatment in psoriatic arthritis:
need for co-medication?
B Michelsen, DM Soldal, A Kavanaugh, DL Boyle, G Haugeberg
30 PP36
The impact of obesity on response and adherence to tumour necrosis
factor-a inhibitors in psoriatic arthritis: results from the DANBIO and
ICEBIO registries
L Dreyer, P Hojgaard, B Glintborg, LE Kristensen, B Gudbjomsson,
TJ Love
31 PP37
The majority of patients with psoriatic arthritis are not eligible for
controlled clinical trials
E Runarsdottir, AI Gunnarsdöttir, PS Gunnarsson, TJ Love,
B Gudbjomsson; on behalf of ICEBIO
31 PP38
The efficacy and safety of ixekizumab, adalimumab, and
placebo in patients with psoriatic arthritis naive to biological
disease-modifying anti-rheumatic drugs: a double-blind
phase 3 study
P Mease, D van der Heijde, C Ritchlin, R Cuchacovich, C Shuler,
C-Y Lin, H Vangerow, S Samanta, CH Lee, D Gladman, E Larsson
33 PP39
Reduction in fatigue in patients with active psoriatic arthritis is
sustained over 2 years: long-term results of two phase 3 studies
of secukinumab
TK Kvien, L Gossec, P Conaghan, M Ostergaard, J Canete, C Gaillez,
S Mpofu, E Davenport, S Jug!
www.scandjrheumatol.dk
Contents
33 PP40
Disease activity and quality of life of patients with psoriatic arthritis
mutilans: the Nordic PAM study
B Gudbjornsson, U Lindqvist, L Iversen, L Pairnela, L Laasonen,
L Ejstrup, T Temowitz, M Stähle
33 PP41
Achilles enthesitis defined by ultrasound is not associated with
clinical enthesitis in patients with psoriatic arthritis
B Michelsen, AP Diamantopoulos, DM Soldat, HB Hammer,
A Kavanaugh, G Haugeberg
34 PP42
Reactive arthritis caused by a weever fish sting: a case report
MJ Velander, SA Just, BA Frederiksen, IMJ Hansen
35 PP43
Plasma calprotectin in SpA patients: a biomarker for peripheral arthritis
IM Hansen, G Bakland, 0 Feme
35 PP44
Reduction in fatigue in patients with active ankylosing spondylitis:
results of two phase 3 studies of secukinumab
TK Kvien, P Conaghan, A Deodhar, L Gossec, M 0stergaard,
J Canete, K Gandhi, H Richards, N Williams, S Jugl
Systemic lupus erythematosus
36 PP45
The value of multidisciplinary reassessment in the attribution of
neuropsychiatric symptoms to SLE: data from the Leiden
NPSLE cohort
C Magro, E Zirkzee, L Beaart-van de Voorde, H Middelkoop,
N van der Wee, H Menno, N Kmyt, E Bollen, M van Buchem,
T Huizinga, G Steup-Beekman
36 PP46
Cutaneous lupus erythematosus and systemic lupus erythematosus
are associated with clinically significant cardiovascular risk:
a Danish nationwide cohort study
JH Hesselvig, 0 Ahlehoff, L Dreyer, G Gislason, K Kofoed
37 PP47
The risk of cardiovascular disease in systemic lupus erythematosus and
lupus nephritis: a Danish nationwide population-based cohort study
M-LF Hermansen, J Lindhardsen, C Torp-Pedersen, M Faurschou,
S Jacobsen
38 PP48
Microparticles bind to circulating phagocytes and erythrocytes: a
possible clearance mechanism relevant to the pathogenesis of
systemic lupus erythematosus
L Kjaer, CH Nielsen, S Jacobsen
38 PP49
Increased levels of microvesicles containing nuclear molecules and
immunoglobulins in patients with systemic lupus erythematosus
FMobarrez, H Wallen, D Pisetsky, I Gunnarsson, J Gustafsson,
A Zickert, A Vikerfors, E Svenungsson
39 PP50
The TNF-a/p-albumin ratio: a suggested biomarker for disease
activity in SLE
E Svenungsson, S Eketfäli H Idborg, JT Gustafsson, A Zickert,
M Kvarnstrom, V Oke, S Pettersson, P-J Jakobsson, I Gunnarsson
40 PP51
Serum ferritin as a marker of clinical and histopathological response
to treatment in lupus nephritis
/ Parodis, H Ding, A Zickert, L Amaud, C Mohan, / Gunnarsson
41 PP52
Antiphospholipid antibodies in lupus nephritis
I Parodis, L Amaud, J Gerhardsson, A Zickert, B Sundelin, If Malmström,
E Svenungsson, I Gunnarsson
42 PP53
Soluble tumour necrosis factor receptor 2 (sTNFR2) as a biomarker of
kidney tissue damage and long-term renal outcome in lupus nephritis
I Parodis, H Ding, A Zickert, L Amaud, E Svenungsson, C Mohan,
I Gunnarsson
43 PP54
Serum insulin-like growth factor-binding protein 2 (IGFBP2) as a biomarker
of clinical and histopathological treatment response in lupus nephritis
I Parodis, H Ding, A Zickert, L Amaud, C Mohan, I Gunnarsson
43 PP55
Serum anexelekto (Axl) as a novel biomarker of renal activity, treatment
response, and long-term outcome in patients with lupus nephritis
I Parodis, H Ding, A Zickert, L Amaud, C Mohan, I Gunnarsson
Systemic inflammatory disorders
44 PP56
A selective JAK1 inhibitor, filgotinib, suppresses lymphocytic infiltration
in salivary gland of NOD mice through suppression of BAFF production
of salivary gland epithelial cells
HK Min, J Lee, J Lee, S-YBaek, JH Koh, M-K Jung, H Jeon, SH Kim,
JH Yoo, H Kim, S-K Kwok, JH Ju, S-H Park
44 PP57
Activation of plasmacytoid dendritic cells by apoptotic particles:
mechanism for the loss of immunological tolerance in androgen-depleted
Sjogren s syndrome
M-M Ainola, P Porola, Y Takakubo, B Przybyla, T Tolvanen,
A Hanninen, Y Konttinen, D Nordstrom
44 PP58
Characterizing the effects of epigenetic regulation in assays using
peripheral blood mononuclear cells from patients with inflammatory
diseases
L Berg, Y Sundström, OAflab, F Bergqvist, K Kultima, M Gustafsson,
RLatsson, MSundström, E Ossipova, J LengqvisL P-J Jakobsson, J Rubin
45 PP59
Risk factors for thromboembolic events (TEs) in patients with idiopathic
inflammatory myopathies (IIM)
A Notarnicola, L Nasman, Q Tang, A Tjarlund, KEIvin, L Berg, JNorkko,
I Lundberg, A Aleksandra
45 PP60
Antiphospholipid antibodies in systemic sclerosis and their association
with ischaemic arterial events and atherosclerosis
AÄH Nordin, S Coskun, A Antovic, K Elvin, E Svenungsson
46 PP61
Pulmonary fibrosis and levels of total IgA in patients with systemic sclerosis
AÄH Nordin, K Gunnarsson, S Nyren, E Svenungsson
46 PP62
Early phenotypic presentation of Blau syndrome
R Abdwani, S AI Zuhaibi, A Saparamadu, K AI Thuhli
www.scandjrheumatol.dk
Contents
46 PP63
Immunogenicity of the 13-valent pneumococcal conjugate vaccine
(Prevenar 13) in patients with primary systemic vasculitis receiving
standard of care therapy and controls
MC Kapetanovic, PNived, J Nagel, P Geborek, GJdnsson, L Skattum,
TSaxne
47 PP64
Mycoplasma infection inducing flare of Behcet s disease in a
young man
RA Andreasen, JB Knudsen, IMJ Hansen
48 PP65
Rituximab-induced hypogammaglobulinaemia and intravenous
immunoglobulin replacement therapy do not protect against
relapse in granulomatous with polyangiitis
E Besada
48 PP66
Enhanced compliance to osteoporosis prophylaxis in
glucocorticoid (GC)-treated polymyalgia rheumatica (PMR)
patients: the role of ongoing follow-up support at nurse
consultations
A Emamifar, SH Jakobsen, RG Mortensen, IMJ Hansen
Pain and fatigue in rheumatic disorders
49 PP67
Lower back pain as an initial symptom of a fatal infection with
leptospirosis
MM Sondergaard, A Tursunovic, P Thye-Renn, IMJ Hansen
49 PP68
Effect of rehabilitation on health status and sleep in women with
fibromyalgia
G Marteinsdottir, N Gudmundsdottir, I Kristjansson, H Bjarnadottir,
B Thodeifsdottir, M Guöjonsdottir
50 PP69
The impact of concomitant fibromyalgia on disease activity composite
indices in rheumatoid arthritis
J Toms, P Bradna, T Soukup, Z Hrncir
50 PP70
Effect of 6 weeks of rehabilitation on health status, stress,
anxiety, and depression in women with fibromyalgia
I Kristjansson, GL Marteinsdottir, NK Gudmundsdottir,
H Bjarnadottir, B Thodeifsdottir, M Gudjonsdottir
51 PP71
A description and study of a physiotherapy residential programme for
Scandinavian patients with rheumatic diseases
BB Braulio
51 PP72
Study of the reparation of the rotator cuff by combining
scaffolds with BMP-2
CAn/inius, YLopiz, MC Rodnguez-Bobada, A Civantos, M Diaz-Moreno,
P Dolz-Gaitön, F Marco
Prize winners reviews
53 The IL-20 receptor axis in immune-mediated inflammatory arthritis:
novel links between innate immune recognition and bone homeostasis
TW Kragstrup
58 Hand osteoarthritis: current knowledge and new ideas
IK Haugen
64 Optimizing biological treatments for rheumatoid arthritis
K Chatzidionysiou
Author Index
76 Author Index
COVER IMAGE Image of Seijalandsfoss, Iceland, created by Diego Delso. Used under Creative Commons license (CC BY-SA 2.0).
www.scandjitieumatol .dk
|
| any_adam_object | 1 |
| author2 | Reynisdóttir, Guðrún Björk |
| author2_role | edt |
| author2_variant | g b r gb gbr |
| author_corporate | Scandinavian Congress of Rheumatology Reykjavik |
| author_corporate_role | aut |
| author_facet | Reynisdóttir, Guðrún Björk Scandinavian Congress of Rheumatology Reykjavik |
| author_sort | Scandinavian Congress of Rheumatology Reykjavik |
| building | Verbundindex |
| bvnumber | BV043826319 |
| ctrlnum | (OCoLC)968257326 (DE-599)BVBBV043826319 |
| format | Conference Proceeding Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01674nam a2200373 cb4500</leader><controlfield tag="001">BV043826319</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20190222 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">161014s2016 a||| |||| 10||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)968257326</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043826319</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="111" ind1="2" ind2=" "><subfield code="a">Scandinavian Congress of Rheumatology</subfield><subfield code="n">36.</subfield><subfield code="d">2016</subfield><subfield code="c">Reykjavik</subfield><subfield code="j">Verfasser</subfield><subfield code="0">(DE-588)1114844047</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Abstracts of the 36th Scandinavian Congress of Rheumatology</subfield><subfield code="b">Reykjavik, Iceland, September 1st-3rd, 2016</subfield><subfield code="c">editors: Guðrún Björk Reynisdóttir, Björn Guðbjörnsson</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Milton Park, Abingdon</subfield><subfield code="b">Taylor & Francis</subfield><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">77 Seiten</subfield><subfield code="b">Illustrationen, Diagramme</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Scandinavian journal of rheumatology : Supplement</subfield><subfield code="v">128</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Rheumatismus</subfield><subfield code="0">(DE-588)4049836-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Rheumatologie</subfield><subfield code="0">(DE-588)4128646-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Rheumatologie</subfield><subfield code="0">(DE-588)4128646-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Rheumatismus</subfield><subfield code="0">(DE-588)4049836-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reynisdóttir, Guðrún Björk</subfield><subfield code="4">edt</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Scandinavian journal of rheumatology</subfield><subfield code="v">Supplement ; 128</subfield><subfield code="w">(DE-604)BV000003191</subfield><subfield code="9">128</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029237208&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029237208</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Konferenzschrift |
| id | DE-604.BV043826319 |
| illustrated | Illustrated |
| indexdate | 2024-07-10T07:36:07Z |
| institution | BVB |
| institution_GND | (DE-588)1114844047 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029237208 |
| oclc_num | 968257326 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | 77 Seiten Illustrationen, Diagramme |
| publishDate | 2016 |
| publishDateSearch | 2016 |
| publishDateSort | 2016 |
| publisher | Taylor & Francis |
| record_format | marc |
| series | Scandinavian journal of rheumatology |
| series2 | Scandinavian journal of rheumatology : Supplement |
| spelling | Scandinavian Congress of Rheumatology 36. 2016 Reykjavik Verfasser (DE-588)1114844047 aut Abstracts of the 36th Scandinavian Congress of Rheumatology Reykjavik, Iceland, September 1st-3rd, 2016 editors: Guðrún Björk Reynisdóttir, Björn Guðbjörnsson Milton Park, Abingdon Taylor & Francis 2016 77 Seiten Illustrationen, Diagramme txt rdacontent n rdamedia nc rdacarrier Scandinavian journal of rheumatology : Supplement 128 Rheumatismus (DE-588)4049836-0 gnd rswk-swf Rheumatologie (DE-588)4128646-7 gnd rswk-swf (DE-588)1071861417 Konferenzschrift gnd-content Rheumatologie (DE-588)4128646-7 s DE-604 Rheumatismus (DE-588)4049836-0 s Reynisdóttir, Guðrún Björk edt Scandinavian journal of rheumatology Supplement ; 128 (DE-604)BV000003191 128 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029237208&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Abstracts of the 36th Scandinavian Congress of Rheumatology Reykjavik, Iceland, September 1st-3rd, 2016 Scandinavian journal of rheumatology Rheumatismus (DE-588)4049836-0 gnd Rheumatologie (DE-588)4128646-7 gnd |
| subject_GND | (DE-588)4049836-0 (DE-588)4128646-7 (DE-588)1071861417 |
| title | Abstracts of the 36th Scandinavian Congress of Rheumatology Reykjavik, Iceland, September 1st-3rd, 2016 |
| title_auth | Abstracts of the 36th Scandinavian Congress of Rheumatology Reykjavik, Iceland, September 1st-3rd, 2016 |
| title_exact_search | Abstracts of the 36th Scandinavian Congress of Rheumatology Reykjavik, Iceland, September 1st-3rd, 2016 |
| title_full | Abstracts of the 36th Scandinavian Congress of Rheumatology Reykjavik, Iceland, September 1st-3rd, 2016 editors: Guðrún Björk Reynisdóttir, Björn Guðbjörnsson |
| title_fullStr | Abstracts of the 36th Scandinavian Congress of Rheumatology Reykjavik, Iceland, September 1st-3rd, 2016 editors: Guðrún Björk Reynisdóttir, Björn Guðbjörnsson |
| title_full_unstemmed | Abstracts of the 36th Scandinavian Congress of Rheumatology Reykjavik, Iceland, September 1st-3rd, 2016 editors: Guðrún Björk Reynisdóttir, Björn Guðbjörnsson |
| title_short | Abstracts of the 36th Scandinavian Congress of Rheumatology |
| title_sort | abstracts of the 36th scandinavian congress of rheumatology reykjavik iceland september 1st 3rd 2016 |
| title_sub | Reykjavik, Iceland, September 1st-3rd, 2016 |
| topic | Rheumatismus (DE-588)4049836-0 gnd Rheumatologie (DE-588)4128646-7 gnd |
| topic_facet | Rheumatismus Rheumatologie Konferenzschrift |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029237208&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000003191 |
| work_keys_str_mv | AT scandinaviancongressofrheumatologyreykjavik abstractsofthe36thscandinaviancongressofrheumatologyreykjavikicelandseptember1st3rd2016 AT reynisdottirguðrunbjork abstractsofthe36thscandinaviancongressofrheumatologyreykjavikicelandseptember1st3rd2016 |